Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of PTEN expression significance in hormone refractory prostate cancer treated with Cetuximab then Docetaxel + Cetuximab
2007-005465-36Phase 2Completed
- Sponsor
- Meletios Athanasios Dimopoulos
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in prostate cancer (PCa), sponsored by Meletios Athanasios Dimopoulos. Primary endpoint: PSA response correlated with PTEN expression. Started Mar 2009; status: completed.
02
Drugs
cetuximab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2007-005465-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005465-36.